Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 130 entries
Sorted by: Best Match Show Resources per page
Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome.

Respiratory medicine case reports

Takeuchi K, Nakayama K, Okano M, Tamada N, Suehiro H, Shinkura Y, Yanaka K, Onishi H, Tanaka H, Shinke T, Emoto N, Hirata KI.
PMID: 29276674
Respir Med Case Rep. 2017 Dec 07;23:55-59. doi: 10.1016/j.rmcr.2017.12.003. eCollection 2018.

Clinical efficacy of combination therapy using vasodilators for pulmonary arterial hypertension (PAH) is well established. However, information on its safety are limited. We experienced a case of primary Sjogren's syndrome associated with PAH where the patient developed pulmonary edema...

Cite
Takeuchi K, Nakayama K, Okano M, et al. Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome. Respir Med Case Rep. 2017;23:55-59doi: 10.1016/j.rmcr.2017.12.003.
Takeuchi, K., Nakayama, K., Okano, M., Tamada, N., Suehiro, H., Shinkura, Y., Yanaka, K., Onishi, H., Tanaka, H., Shinke, T., Emoto, N., & Hirata, K. I. (2018). Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome. Respiratory medicine case reports, 2355-59. https://doi.org/10.1016/j.rmcr.2017.12.003
Takeuchi, Kimikazu, et al. "Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome." Respiratory medicine case reports vol. 23 (2018): 55-59. doi: https://doi.org/10.1016/j.rmcr.2017.12.003
Takeuchi K, Nakayama K, Okano M, Tamada N, Suehiro H, Shinkura Y, Yanaka K, Onishi H, Tanaka H, Shinke T, Emoto N, Hirata KI. Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome. Respir Med Case Rep. 2017 Dec 07;23:55-59. doi: 10.1016/j.rmcr.2017.12.003. eCollection 2018. PMID: 29276674; PMCID: PMC5730424.
Copy Download .nbib Format: NLM
Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease.

Respiratory medicine case reports

Goobie GC, Sirrs SM, Yee J, English JC, Bergeron C, Nador R, Swiston JR, Mistry PK, Paquin W, Levy RD.
PMID: 31334026
Respir Med Case Rep. 2019 Jun 29;28:100893. doi: 10.1016/j.rmcr.2019.100893. eCollection 2019.

BACKGROUND: Gaucher disease type 1 (GD1) is a lysosomal storage disease rarely resulting in end stage pulmonary hypertension (PH) and interstitial lung disease. There have only been two previous case reports of patients with GD1 receiving lung transplants.CASE PRESENTATION:...

Cite
Goobie GC, Sirrs SM, Yee J, et al. Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease. Respir Med Case Rep. 2019;28:100893doi: 10.1016/j.rmcr.2019.100893.
Goobie, G. C., Sirrs, S. M., Yee, J., English, J. C., Bergeron, C., Nador, R., Swiston, J. R., Mistry, P. K., Paquin, W., & Levy, R. D. (2019). Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease. Respiratory medicine case reports, 28100893. https://doi.org/10.1016/j.rmcr.2019.100893
Goobie, Gillian C, et al. "Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease." Respiratory medicine case reports vol. 28 (2019): 100893. doi: https://doi.org/10.1016/j.rmcr.2019.100893
Goobie GC, Sirrs SM, Yee J, English JC, Bergeron C, Nador R, Swiston JR, Mistry PK, Paquin W, Levy RD. Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease. Respir Med Case Rep. 2019 Jun 29;28:100893. doi: 10.1016/j.rmcr.2019.100893. eCollection 2019. PMID: 31334026; PMCID: PMC6624456.
Copy Download .nbib Format: NLM
Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension.

Pulmonary circulation

Hopper RK, Wang Y, DeMatteo V, Santo A, Kawut SM, Elci OU, Hanna BD, Mercer-Rosa L.
PMID: 29480089
Pulm Circ. 2018 Apr-Jun;8(2):2045894018759247. doi: 10.1177/2045894018759247. Epub 2018 Feb 26.

Pulmonary hypertension (PH) causes significant morbidity and mortality in children due to right ventricular (RV) failure. We sought to determine the effect of prostacyclin analogues on RV function assessed by echocardiography in children with PH. We conducted a retrospective...

Cite
Hopper RK, Wang Y, DeMatteo V, et al. Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. Pulm Circ. 2018;8(2):2045894018759247doi: 10.1177/2045894018759247.
Hopper, R. K., Wang, Y., DeMatteo, V., Santo, A., Kawut, S. M., Elci, O. U., Hanna, B. D., & Mercer-Rosa, L. (2018). Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. Pulmonary circulation, 8(2), 2045894018759247. https://doi.org/10.1177/2045894018759247
Hopper, Rachel K, et al. "Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension." Pulmonary circulation vol. 8,2 (2018): 2045894018759247. doi: https://doi.org/10.1177/2045894018759247
Hopper RK, Wang Y, DeMatteo V, Santo A, Kawut SM, Elci OU, Hanna BD, Mercer-Rosa L. Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. Pulm Circ. 2018 Apr-Jun;8(2):2045894018759247. doi: 10.1177/2045894018759247. Epub 2018 Feb 26. PMID: 29480089; PMCID: PMC5843105.
Copy Download .nbib Format: NLM
Right ventricular ST-elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension.

Pulmonary circulation

Zhan Y, Burstein B, Abualsaud AO, Nosair M, Hirsch AM, Lesenko L, Langleben D.
PMID: 28597772
Pulm Circ. 2017 Apr-Jun;7(2):555-558. doi: 10.1177/2045893217704435. Epub 2017 May 12.

A 32-year-old woman with advanced idiopathic pulmonary arterial hypertension (PAH), treated with oral tadalafil and intravenous epoprostenol, presented with typical angina pectoris of one day's duration. Her electrocardiogram, previously typical of pulmonary hypertension, revealed an acute ST-elevation myocardial infarction...

Cite
Zhan Y, Burstein B, Abualsaud AO, et al. Right ventricular ST-elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension. Pulm Circ. 2017;7(2):555-558doi: 10.1177/2045893217704435.
Zhan, Y., Burstein, B., Abualsaud, A. O., Nosair, M., Hirsch, A. M., Lesenko, L., & Langleben, D. (2017). Right ventricular ST-elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension. Pulmonary circulation, 7(2), 555-558. https://doi.org/10.1177/2045893217704435
Zhan, Yang, et al. "Right ventricular ST-elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension." Pulmonary circulation vol. 7,2 (2017): 555-558. doi: https://doi.org/10.1177/2045893217704435
Zhan Y, Burstein B, Abualsaud AO, Nosair M, Hirsch AM, Lesenko L, Langleben D. Right ventricular ST-elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension. Pulm Circ. 2017 Apr-Jun;7(2):555-558. doi: 10.1177/2045893217704435. Epub 2017 May 12. PMID: 28597772; PMCID: PMC5467937.
Copy Download .nbib Format: NLM
Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart.

Pulmonary circulation

Holmboe S, Andersen A, Jensen RV, Kimose HH, Ilkjær LB, Shen L, Clapp LH, Nielsen-Kudsk JE.
PMID: 28597773
Pulm Circ. 2017 Apr-Jun;7(2):339-347. doi: 10.1177/2045893217691532. Epub 2017 May 30.

Prostacyclins are vasodilatory agents used in the treatment of pulmonary arterial hypertension. The direct effects of prostacyclins on right heart function are still not clarified. The aim of this study was to investigate the possible direct inotropic properties of...

Cite
Holmboe S, Andersen A, Jensen RV, et al. Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart. Pulm Circ. 2017;7(2):339-347doi: 10.1177/2045893217691532.
Holmboe, S., Andersen, A., Jensen, R. V., Kimose, H. H., Ilkjær, L. B., Shen, L., Clapp, L. H., & Nielsen-Kudsk, J. E. (2017). Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart. Pulmonary circulation, 7(2), 339-347. https://doi.org/10.1177/2045893217691532
Holmboe, Sarah, et al. "Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart." Pulmonary circulation vol. 7,2 (2017): 339-347. doi: https://doi.org/10.1177/2045893217691532
Holmboe S, Andersen A, Jensen RV, Kimose HH, Ilkjær LB, Shen L, Clapp LH, Nielsen-Kudsk JE. Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart. Pulm Circ. 2017 Apr-Jun;7(2):339-347. doi: 10.1177/2045893217691532. Epub 2017 May 30. PMID: 28597773; PMCID: PMC5467920.
Copy Download .nbib Format: NLM
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH).

Pulmonary circulation

Calcaianu G, Calcaianu M, Canuet M, Enache I, Kessler R.
PMID: 28597752
Pulm Circ. 2017 Apr-Jun;7(2):439-447. doi: 10.1177/2045893217702401. Epub 2017 Mar 13.

Once initiated for pulmonary arterial hypertension (PAH), epoprostenol treatment usually needs to be delivered for an indefinite duration. It is possible that some participants could be transitioned from epoprostenol to oral therapies. We retrospectively evaluated eight PAH participants transitioned...

Cite
Calcaianu G, Calcaianu M, Canuet M, et al. Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH). Pulm Circ. 2017;7(2):439-447doi: 10.1177/2045893217702401.
Calcaianu, G., Calcaianu, M., Canuet, M., Enache, I., & Kessler, R. (2017). Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH). Pulmonary circulation, 7(2), 439-447. https://doi.org/10.1177/2045893217702401
Calcaianu, George, et al. "Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)." Pulmonary circulation vol. 7,2 (2017): 439-447. doi: https://doi.org/10.1177/2045893217702401
Calcaianu G, Calcaianu M, Canuet M, Enache I, Kessler R. Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH). Pulm Circ. 2017 Apr-Jun;7(2):439-447. doi: 10.1177/2045893217702401. Epub 2017 Mar 13. PMID: 28597752; PMCID: PMC5467933.
Copy Download .nbib Format: NLM
Moderate and deep hypothermia produces hyporesposiveness to phenylephrine in isolated rat aorta.

The Korean journal of thoracic and cardiovascular surgery

Cho JW, Lee CH, Jang JS, Kwon OC, Roh WS, Kim JE.
PMID: 24368966
Korean J Thorac Cardiovasc Surg. 2013 Dec;46(6):402-12. doi: 10.5090/kjtcs.2013.46.6.402. Epub 2013 Dec 06.

BACKGROUND: Moderate and severe hypothermia with cardiopulmonary bypass during aortic surgery can cause some complications such as endothelial cell dysfunction or coagulation disorders. This study found out the difference of vascular reactivity by phenylephrine in moderate and severe hypothermia.METHODS:...

Cite
Cho JW, Lee CH, Jang JS, et al. Moderate and deep hypothermia produces hyporesposiveness to phenylephrine in isolated rat aorta. Korean J Thorac Cardiovasc Surg. 2013;46(6):402-12doi: 10.5090/kjtcs.2013.46.6.402.
Cho, J. W., Lee, C. H., Jang, J. S., Kwon, O. C., Roh, W. S., & Kim, J. E. (2013). Moderate and deep hypothermia produces hyporesposiveness to phenylephrine in isolated rat aorta. The Korean journal of thoracic and cardiovascular surgery, 46(6), 402-12. https://doi.org/10.5090/kjtcs.2013.46.6.402
Cho, Jun Woo, et al. "Moderate and deep hypothermia produces hyporesposiveness to phenylephrine in isolated rat aorta." The Korean journal of thoracic and cardiovascular surgery vol. 46,6 (2013): 402-12. doi: https://doi.org/10.5090/kjtcs.2013.46.6.402
Cho JW, Lee CH, Jang JS, Kwon OC, Roh WS, Kim JE. Moderate and deep hypothermia produces hyporesposiveness to phenylephrine in isolated rat aorta. Korean J Thorac Cardiovasc Surg. 2013 Dec;46(6):402-12. doi: 10.5090/kjtcs.2013.46.6.402. Epub 2013 Dec 06. PMID: 24368966; PMCID: PMC3868687.
Copy Download .nbib Format: NLM
Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics.

Pulmonary circulation

White RJ, Levin Y, Wessman K, Heininger A, Frutiger K.
PMID: 24618545
Pulm Circ. 2013 Sep;3(3):611-21. doi: 10.1086/674304. Epub 2013 Nov 18.

Abstract Continuous prostanoid infusions are recommended for patients with advanced pulmonary arterial hypertension. Infusion site pain has discouraged some physicians from considering subcutaneous (SQ) treprostinil therapy even though it has safety and convenience advantages over intravenous epoprostenol. We conducted...

Cite
White RJ, Levin Y, Wessman K, et al. Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Pulm Circ. 2013;3(3):611-21doi: 10.1086/674304.
White, R. J., Levin, Y., Wessman, K., Heininger, A., & Frutiger, K. (2013). Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Pulmonary circulation, 3(3), 611-21. https://doi.org/10.1086/674304
White, R James, et al. "Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics." Pulmonary circulation vol. 3,3 (2013): 611-21. doi: https://doi.org/10.1086/674304
White RJ, Levin Y, Wessman K, Heininger A, Frutiger K. Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Pulm Circ. 2013 Sep;3(3):611-21. doi: 10.1086/674304. Epub 2013 Nov 18. PMID: 24618545; PMCID: PMC4070817.
Copy Download .nbib Format: NLM
Pulmonary Arterial Hypertension: New Management Options.

Current treatment options in cardiovascular medicine

Huffman MD, McLaughlin VV.
PMID: 15496262
Curr Treat Options Cardiovasc Med. 2004 Dec;6(6):451-458. doi: 10.1007/s11936-004-0002-y.

The past decade has realized remarkable advances in the treatment of pulmonary arterial hypertension (PAH), a progressive and potentially fatal disease. A small proportion of patients will have a dramatic hemodynamic response to acute vasodilator testing performed at the...

Cite
Huffman MD, McLaughlin VV. Pulmonary Arterial Hypertension: New Management Options. Curr Treat Options Cardiovasc Med. 2004;6(6):451-458doi: 10.1007/s11936-004-0002-y.
Huffman, M. D., & McLaughlin, V. V. (2004). Pulmonary Arterial Hypertension: New Management Options. Current treatment options in cardiovascular medicine, 6(6), 451-458. https://doi.org/10.1007/s11936-004-0002-y
Huffman, Mark D, and McLaughlin, Vallerie V. "Pulmonary Arterial Hypertension: New Management Options." Current treatment options in cardiovascular medicine vol. 6,6 (2004): 451-458. doi: https://doi.org/10.1007/s11936-004-0002-y
Huffman MD, McLaughlin VV. Pulmonary Arterial Hypertension: New Management Options. Curr Treat Options Cardiovasc Med. 2004 Dec;6(6):451-458. doi: 10.1007/s11936-004-0002-y. PMID: 15496262.
Copy Download .nbib Format: NLM
Epoprostenol increased mortality in patients with severe CHF.

Evidence-based cardiovascular medicine

Sharpe N.
PMID: 16379790
Evid Based Cardiovasc Med. 1998 Mar;2(1):26. doi: 10.1016/s1361-2611(98)80023-7.

No abstract available.

Cite
Sharpe N. Epoprostenol increased mortality in patients with severe CHF. Evid Based Cardiovasc Med. 1998;2(1):26doi: 10.1016/s1361-2611(98)80023-7.
Sharpe, N. (1998). Epoprostenol increased mortality in patients with severe CHF. Evidence-based cardiovascular medicine, 2(1), 26. https://doi.org/10.1016/s1361-2611(98)80023-7
Sharpe, N. "Epoprostenol increased mortality in patients with severe CHF." Evidence-based cardiovascular medicine vol. 2,1 (1998): 26. doi: https://doi.org/10.1016/s1361-2611(98)80023-7
Sharpe N. Epoprostenol increased mortality in patients with severe CHF. Evid Based Cardiovasc Med. 1998 Mar;2(1):26. doi: 10.1016/s1361-2611(98)80023-7. PMID: 16379790.
Copy Download .nbib Format: NLM
Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan.

Therapeutics and clinical risk management

Schuuring MJ, Vis JC, Duffels MG, Bouma BJ, Mulder BJ.
PMID: 20856682
Ther Clin Risk Manag. 2010 Sep 07;6:359-66. doi: 10.2147/tcrm.s8397.

Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival outcome. PAH is classified by the 2009 updated clinical classification of pulmonary hypertension and a major subgroup is PAH due to congenital heart disease (CHD) with systemic-to-pulmonary shunt....

Cite
Schuuring MJ, Vis JC, Duffels MG, et al. Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag. 2010;6:359-66doi: 10.2147/tcrm.s8397.
Schuuring, M. J., Vis, J. C., Duffels, M. G., Bouma, B. J., & Mulder, B. J. (2010). Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Therapeutics and clinical risk management, 6359-66. https://doi.org/10.2147/tcrm.s8397
Schuuring, Mark J, et al. "Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan." Therapeutics and clinical risk management vol. 6 (2010): 359-66. doi: https://doi.org/10.2147/tcrm.s8397
Schuuring MJ, Vis JC, Duffels MG, Bouma BJ, Mulder BJ. Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag. 2010 Sep 07;6:359-66. doi: 10.2147/tcrm.s8397. PMID: 20856682; PMCID: PMC2940744.
Copy Download .nbib Format: NLM
The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension.

Journal of medical ultrasonics (2001)

Morishita T, Miyaji K, Akao I, Fujita K, Nakayama H, Hisamatsu K, Munemasa M, Fujimoto Y, Matsubara H.
PMID: 27277440
J Med Ultrason (2001). 2009 Dec;36(4):201-6. doi: 10.1007/s10396-009-0228-0. Epub 2009 Aug 15.

PURPOSE: Echocardiography is useful not only for detecting pulmonary hypertension (PH) but also for estimating the severity of PH by evaluating various morphological changes of the heart caused by pressure and volume overload and by ventricular interaction. We investigated...

Cite
Morishita T, Miyaji K, Akao I, et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. J Med Ultrason (2001). 2009;36(4):201-6doi: 10.1007/s10396-009-0228-0.
Morishita, T., Miyaji, K., Akao, I., Fujita, K., Nakayama, H., Hisamatsu, K., Munemasa, M., Fujimoto, Y., & Matsubara, H. (2009). The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. Journal of medical ultrasonics (2001), 36(4), 201-6. https://doi.org/10.1007/s10396-009-0228-0
Morishita, Takashi, et al. "The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension." Journal of medical ultrasonics (2001) vol. 36,4 (2009): 201-6. doi: https://doi.org/10.1007/s10396-009-0228-0
Morishita T, Miyaji K, Akao I, Fujita K, Nakayama H, Hisamatsu K, Munemasa M, Fujimoto Y, Matsubara H. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. J Med Ultrason (2001). 2009 Dec;36(4):201-6. doi: 10.1007/s10396-009-0228-0. Epub 2009 Aug 15. PMID: 27277440.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 130 entries